| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S11523-017-0481-X |
| P698 | PubMed publication ID | 28281220 |
| P50 | author | Rajasekharan Somasundaram | Q47099159 |
| P2093 | author name string | Jennifer Sims-Mourtada | |
| Kimberly M Arnold | |||
| Nicole J Flynn | |||
| P2860 | cites work | Antigen recognition and allogeneic tumor rejection in CD8+ TCR transgenic/RAG(-/-) mice | Q73873342 |
| Tumor-infiltrating B-cell-derived IgG recognizes tumor components in human lung cancer | Q74100278 | ||
| Clinical significance of serum P53 antibody in patients with gastric cancer | Q74383364 | ||
| Clinical implications of serum anti-p53 antibodies for patients with gastric carcinoma | Q74451695 | ||
| CD8+ tumor-infiltrating lymphocytes together with CD4+ tumor-infiltrating lymphocytes and dendritic cells improve the prognosis of patients with pancreatic adenocarcinoma | Q75225386 | ||
| CD8+ T cells infiltrated within cancer cell nests as a prognostic factor in human colorectal cancer | Q77168314 | ||
| Tumor-infiltrating B lymphocytes as a potential source of identifying tumor antigen in human lung cancer | Q77815942 | ||
| Effect of IgG produced by tumor-infiltrating B lymphocytes on lung tumor growth | Q79856196 | ||
| An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model | Q80183564 | ||
| Serum immunoglobulin G fraction 4 levels in pancreatic cancer: elevations not associated with autoimmune pancreatitis | Q80463664 | ||
| The humoral immune system has a key prognostic impact in node-negative breast cancer | Q81561686 | ||
| Prognostic effect of epithelial and stromal lymphocyte infiltration in non-small cell lung cancer | Q81774016 | ||
| The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice | Q83822496 | ||
| The prognostic value of intraepithelial and stromal CD3-, CD117- and CD138-positive cells in non-small cell lung carcinoma | Q84240595 | ||
| Pathologic significance of immunoglobulin G4-positive plasma cells in extrahepatic cholangiocarcinoma | Q84249129 | ||
| IgG4 syndrome: old disease, new perspective | Q84512423 | ||
| Prognostic impact of B-cell density in cutaneous melanoma | Q84584206 | ||
| Four cases of rituximab-associated melanoma | Q87703555 | ||
| A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma | Q87718370 | ||
| A subset of host B lymphocytes controls melanoma metastasis through a melanoma cell adhesion molecule/MUC18-dependent interaction: evidence from mice and humans | Q24642053 | ||
| B cell regulation of the anti-tumor response and role in carcinogenesis | Q26738867 | ||
| Cancer immunotherapy: the beginning of the end of cancer? | Q26752277 | ||
| IgG4 Characteristics and Functions in Cancer Immunity | Q26770244 | ||
| Tertiary Lymphoid Structures in Cancers: Prognostic Value, Regulation, and Manipulation for Therapeutic Intervention | Q28073895 | ||
| A seven-marker signature and clinical outcome in malignant melanoma: a large-scale tissue-microarray study with two independent patient cohorts | Q28728722 | ||
| Immunotype and immunohistologic characteristics of tumor-infiltrating immune cells are associated with clinical outcome in metastatic melanoma | Q30422102 | ||
| The tumor-infiltrating B cell response in medullary breast cancer is oligoclonal and directed against the autoantigen actin exposed on the surface of apoptotic cancer cells. | Q31018962 | ||
| Antigen-driven oligoclonal expansion of tumor-infiltrating B cells in infiltrating ductal carcinoma of the breast | Q31102204 | ||
| Antigen-specific IgG antibodies in stage IV long-time survival breast cancer patients. | Q31937913 | ||
| Evidence for an antigen-driven humoral immune response in medullary ductal breast cancer. | Q32028187 | ||
| Tumor-infiltrating B lymphocytes as an efficient source of highly specific immunoglobulins recognizing tumor cells. | Q33303060 | ||
| Tumor infiltrating lymphocytes: an intriguing player in the survival of colorectal cancer patients | Q33552813 | ||
| Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer | Q33584033 | ||
| CD40-activated B cells induce anti-tumor immunity in vivo | Q33709425 | ||
| B cells and ectopic follicular structures: novel players in anti-tumor programming with prognostic power for patients with metastatic colorectal cancer | Q33721433 | ||
| Preclinical and clinical development of DNA vaccines for prostate cancer | Q33740811 | ||
| Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. | Q33788520 | ||
| B cell subsets and dysfunction of regulatory B cells in IgG4-related diseases and primary Sjögren's syndrome: the similarities and differences | Q33822678 | ||
| The immune microenvironment of breast ductal carcinoma in situ | Q33834968 | ||
| Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer | Q33916814 | ||
| The role of CD40 in peripheral T cell tolerance and immunity | Q34067144 | ||
| Lipopolysaccharide-activated B cells down-regulate Th1 immunity and prevent autoimmune diabetes in nonobese diabetic mice | Q34083166 | ||
| CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients | Q34093165 | ||
| Characterization of tumor-associated B-cell subsets in patients with colorectal cancer | Q34103969 | ||
| Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. | Q34144779 | ||
| Acute depletion of activated memory B cells involves the PD-1 pathway in rapidly progressing SIV-infected macaques. | Q34245386 | ||
| B-cell biology and development | Q34331269 | ||
| Revisiting the B-cell compartment in mouse and humans: more than one B-cell subset exists in the marginal zone and beyond. | Q34495557 | ||
| Enhanced frequency and potential mechanism of B regulatory cells in patients with lung cancer | Q34537331 | ||
| Prognostic significance of B-cells and pSTAT3 in patients with ovarian cancer | Q34552079 | ||
| Dual roles for immune metagenes in breast cancer prognosis and therapy prediction | Q34558758 | ||
| Multiplexed quantitative analysis of CD3, CD8, and CD20 predicts response to neoadjuvant chemotherapy in breast cancer | Q34616067 | ||
| Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors | Q34616576 | ||
| Elevated serum IgG4 defines specific clinical phenotype of rheumatoid arthritis | Q34754719 | ||
| B cells promote tumor progression via STAT3 regulated-angiogenesis | Q34755398 | ||
| A regulatory B cell subset with a unique CD1dhiCD5+ phenotype controls T cell-dependent inflammatory responses | Q34778834 | ||
| Tumor-infiltrating lymphocytes in colorectal cancers with microsatellite instability are correlated with the number and spectrum of frameshift mutations. | Q34985439 | ||
| Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells | Q34987934 | ||
| Attenuation of HIV-associated human B cell exhaustion by siRNA downregulation of inhibitory receptors | Q35080089 | ||
| Tertiary Lymphoid Structure-Associated B Cells are Key Players in Anti-Tumor Immunity | Q35110486 | ||
| The human marginal zone B cell | Q35119920 | ||
| Regulatory B cells are induced by gut microbiota-driven interleukin-1β and interleukin-6 production | Q35345421 | ||
| Clinical applications of DNA vaccines: current progress | Q35452312 | ||
| A clinically relevant gene signature in triple negative and basal-like breast cancer | Q35683578 | ||
| Analysis of the mononuclear inflammatory cell infiltrate in the normal breast, benign proliferative breast disease, in situ and infiltrating ductal breast carcinomas: preliminary observations | Q35770336 | ||
| Expansion of autoreactive unresponsive CD21-/low B cells in Sjögren's syndrome-associated lymphoproliferation | Q35776056 | ||
| Immune microenvironment as a factor of breast cancer progression. | Q35780464 | ||
| Immune and Inflammatory Cell Composition of Human Lung Cancer Stroma | Q35790271 | ||
| Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy | Q35849866 | ||
| Regulatory B cells preferentially accumulate in tumor-draining lymph nodes and promote tumor growth | Q35866355 | ||
| The relationship between serum p53 autoantibodies and characteristics of human breast cancer | Q35979208 | ||
| B-lymphocytes, innate immunity, and autoimmunity | Q35982429 | ||
| Immunosuppressive and Prometastatic Functions of Myeloid-Derived Suppressive Cells Rely upon Education from Tumor-Associated B Cells. | Q36021465 | ||
| Elevated IgG4 in patient circulation is associated with the risk of disease progression in melanoma | Q36110293 | ||
| CD4+ and CD8+ T cells have opposing roles in breast cancer progression and outcome | Q36232078 | ||
| CD8+ lymphocyte infiltration is an independent favorable prognostic indicator in basal-like breast cancer | Q36245546 | ||
| Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer | Q36292740 | ||
| A case for regulatory B cells | Q36360842 | ||
| Regulatory B cells control T-cell autoimmunity through IL-21-dependent cognate interactions. | Q36385029 | ||
| In situ hybridisation and S1 mapping show that the presence of infiltrating plasma cells is associated with poor prognosis in breast cancer | Q36440712 | ||
| CD19+CD24hiCD38hiBregs involved in downregulate helper T cells and upregulate regulatory T cells in gastric cancer | Q36545192 | ||
| Mucin 1-specific B cell immune responses and their impact on overall survival in breast cancer patients | Q36597345 | ||
| PD-L1 mediated the differentiation of tumor-infiltrating CD19(+) B lymphocytes and T cells in Invasive breast cancer | Q36711049 | ||
| IgG4 subclass antibodies impair antitumor immunity in melanoma. | Q36733452 | ||
| Regulatory B cells contribute to the impaired antitumor immunity in ovarian cancer patients | Q40241255 | ||
| Anti-tumor immunity in B lymphocyte-deprived mice. I. Immunity to a chemically induced tumor | Q40683067 | ||
| Prognostic impact of tumour-infiltrating B cells and plasma cells in colorectal cancer | Q40802902 | ||
| Ex vivo removal of serum igg in a patient with colon carcinoma.Some biochemical, immunological and histological observations | Q40908350 | ||
| Plasma cells in primary melanoma. Prognostic significance and possible role of IgA. | Q40915404 | ||
| Mammary-tumor-educated B cells acquire LAP/TGF-β and PD-L1 expression and suppress anti-tumor immune responses | Q40982736 | ||
| Tumor-infiltrating CD8(+) T lymphocytes associated with clinical outcome in anal squamous cell carcinoma | Q41044428 | ||
| Autoantibodies, autoimmunity and cancer (review). | Q41736789 | ||
| Serum exosomes and cytokines promote a T-helper cell type 2 environment in the peripheral blood of glioblastoma patients | Q42234796 | ||
| The prognostic significance of B lymphocytes in invasive carcinoma of the breast. | Q42489904 | ||
| Prognostic evaluation of the B cell/IL-8 metagene in different intrinsic breast cancer subtypes | Q42517986 | ||
| Anti-p53 antibodies in serum: relationship to tumor biology and prognosis of breast cancer patients | Q43274816 | ||
| CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation | Q43406136 | ||
| B lymphocyte inhibition of anti-tumor response depends on expansion of Treg but is independent of B-cell IL-10 secretion | Q43418649 | ||
| Neogenesis of lymphoid structures and antibody responses occur in human melanoma metastases. | Q43785551 | ||
| Clinical value of CA 15-3, mucin-like carcinoma-associated antigen, tumor polypeptide antigen, and carcinoembryonic antigen in monitoring early breast cancer patients | Q43900276 | ||
| Dendritic cells in tumor-associated tertiary lymphoid structures signal a Th1 cytotoxic immune contexture and license the positive prognostic value of infiltrating CD8+ T cells | Q44200118 | ||
| Clinical implications of the tumor-infiltrating lymphocyte subsets in colorectal cancer | Q44533312 | ||
| Prognostic significance of circulating P53 antibodies in patients undergoing surgery for locoregional breast cancer. | Q44540976 | ||
| CD4 helper T cells, CD8 cytotoxic T cells, and FOXP3(+) regulatory T cells with respect to lethal prostate cancer | Q44705573 | ||
| Prognostic value of intratumoral CD8+ T lymphocyte in extrahepatic bile duct carcinoma as essential immune response | Q44751335 | ||
| Stromal plasma cells expressing immunoglobulin G4 subclass in non-small cell lung cancer | Q45248991 | ||
| The prognostic relevance of tumour-infiltrating plasma cells and immunoglobulin kappa C indicates an important role of the humoral immune response in non-small cell lung cancer | Q45792488 | ||
| De novo carcinogenesis promoted by chronic inflammation is B lymphocyte dependent | Q46068963 | ||
| The calcium sensors STIM1 and STIM2 control B cell regulatory function through interleukin-10 production | Q46938631 | ||
| Depletion of normal B cells with rituximab as an adjunct to IL-2 therapy for renal cell carcinoma and melanoma | Q47324803 | ||
| Beneficial effect of T follicular helper cells on antibody class switching of B cells in prostate cancer. | Q50762381 | ||
| Crosstalk between B16 melanoma cells and B-1 lymphocytes induces global changes in tumor cell gene expression. | Q50941455 | ||
| CD20+ tumor-infiltrating lymphocytes have an atypical CD27- memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. | Q50955882 | ||
| Characterization of chemokines and adhesion molecules associated with T cell presence in tertiary lymphoid structures in human lung cancer. | Q50993488 | ||
| The level of IgG antibodies reactive to TF, Tn and alpha-Gal polyacrylamide-glycoconjugates in breast cancer patients: relation to survival. | Q51674130 | ||
| Tolerant beekeepers display venom-specific functional IgG4 antibodies in the absence of specific IgE. | Q52744865 | ||
| Comprehensive Immune Profiling of Lung Adenocarcinomas Reveals Four Immunosubtypes with Plasma Cell Subtype a Negative Indicator. | Q52888154 | ||
| Focused antibody response in plasma cell-infiltrated non-medullary (NOS) breast cancers. | Q53020046 | ||
| Human CD19(+)CD25(high) B regulatory cells suppress proliferation of CD4(+) T cells and enhance Foxp3 and CTLA-4 expression in T-regulatory cells. | Q53200046 | ||
| Mice lacking endogenous IL-10-producing regulatory B cells develop exacerbated disease and present with an increased frequency of Th1/Th17 but a decrease in regulatory T cells. | Q53256514 | ||
| NK- and B-cell infiltration correlates with worse outcome in metastatic ovarian carcinoma. | Q53257187 | ||
| Predominant infiltration of macrophages and CD8(+) T Cells in cancer nests is a significant predictor of survival in stage IV nonsmall cell lung cancer. | Q53462850 | ||
| Tumor-infiltrating lymphocytes predict cutaneous melanoma survival. | Q53522148 | ||
| B cells inhibit induction of T cell-dependent tumor immunity. | Q53682449 | ||
| Leukocyte infiltration and tumor cell plasticity are parameters of aggressiveness in primary cutaneous melanoma. | Q54133911 | ||
| Survival in early breast cancer patients is favorably influenced by a natural humoral immune response to polymorphic epithelial mucin. | Q54134074 | ||
| Differential expression of immune-related markers in breast cancer by molecular phenotypes. | Q54465363 | ||
| Immunoglobulin variable regions usage by B-lymphocytes infiltrating a human breast medullary carcinoma | Q56966481 | ||
| Toll-like receptor 2 induces mucosal homing receptor expression and IgA production by human B cells | Q57123088 | ||
| A Comprehensive Analysis of Human Gene Expression Profiles Identifies Stromal Immunoglobulin C as a Compatible Prognostic Marker in Human Solid Tumors | Q59265232 | ||
| CD4+ and B lymphocytes in transplantation immunity. II. Augmented rejection of tumor allografts by mice lacking B cells | Q72222855 | ||
| B lymphocyte pathology in human colorectal cancer. Experimental and clinical therapeutic effects of partial B cell depletion | Q73343324 | ||
| B cells activated by lipopolysaccharide, but not by anti-Ig and anti-CD40 antibody, induce anergy in CD8+ T cells: role of TGF-beta 1 | Q73496358 | ||
| Antigen-driven clonal proliferation, somatic hypermutation, and selection of B lymphocytes infiltrating human ductal breast carcinomas | Q73537019 | ||
| Tumor-associated lymphocytes predict response to neoadjuvant chemotherapy in breast cancer patients | Q36763988 | ||
| Prognostic impact of tumour-associated B cells and plasma cells in epithelial ovarian cancer | Q36769318 | ||
| Evidence for HIV-associated B cell exhaustion in a dysfunctional memory B cell compartment in HIV-infected viremic individuals | Q36851936 | ||
| Cross-platform comparison of independent datasets identifies an immune signature associated with improved survival in metastatic melanoma | Q37046631 | ||
| The relationship between lymphocyte subsets and clinico-pathological determinants of survival in patients with primary operable invasive ductal breast cancer | Q37182278 | ||
| IgG4 antibodies and cancer-associated inflammation: Insights into a novel mechanism of immune escape | Q37195202 | ||
| Human B cell subsets | Q37260869 | ||
| Breast cancer lung metastasis requires expression of chemokine receptor CCR4 and regulatory T cells. | Q37346143 | ||
| PD-L1 is a critical mediator of regulatory B cells and T cells in invasive breast cancer. | Q37352695 | ||
| Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation | Q37422374 | ||
| Regulatory T cells: major players in the tumor microenvironment | Q37515901 | ||
| Co-expression of CD40L with CD70 or OX40L increases B-cell viability and antitumor efficacy | Q37564683 | ||
| Differences in tumor regulatory T-cell localization and activation status impact patient outcome. | Q37609835 | ||
| Progressive changes in composition of lymphocytes in lung tissues from patients with non-small-cell lung cancer | Q37687671 | ||
| B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines | Q37708724 | ||
| CD20+ B cells: the other tumor-infiltrating lymphocytes | Q37801779 | ||
| Melanoma and rituximab: an incidental association? | Q38128645 | ||
| Cholangiocarcinoma with respect to IgG4 Reaction | Q38240871 | ||
| Tumor-associated B cells in cutaneous primary melanoma and improved clinical outcome | Q38380834 | ||
| Tumor infiltrating B-cells are increased in prostate cancer tissue | Q38393120 | ||
| Anti-tumor antibody produced by human tumor-infiltrating and peripheral blood B lymphocytes | Q38468356 | ||
| Regulatory B cells in anti-tumor immunity | Q38497066 | ||
| CD19(+)IL-10(+) regulatory B cells affect survival of tongue squamous cell carcinoma patients and induce resting CD4(+) T cells to CD4(+)Foxp3(+) regulatory T cells | Q38814703 | ||
| Regulatory B cells accelerate hepatocellular carcinoma progression via CD40/CD154 signaling pathway | Q38949223 | ||
| Wildtype p53-specific antibody and T-cell responses in cancer patients | Q39459881 | ||
| Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer | Q39547277 | ||
| The absence of B lymphocytes reduces the number and function of T-regulatory cells and enhances the anti-tumor response in a murine tumor model | Q39604863 | ||
| A Strong B-cell Response Is Part of the Immune Landscape in Human High-Grade Serous Ovarian Metastases | Q39646994 | ||
| Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer | Q39741066 | ||
| B-cell depletion using an anti-CD20 antibody augments antitumor immune responses and immunotherapy in nonhematopoetic murine tumor models | Q39984600 | ||
| B-1 lymphocytes increase metastatic behavior of melanoma cells through the extracellular signal-regulated kinase pathway | Q40007210 | ||
| Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer | Q40111767 | ||
| Interrogation of individual intratumoral B lymphocytes from lung cancer patients for molecular target discovery | Q40135155 | ||
| P433 | issue | 2 | |
| P304 | page(s) | 139-152 | |
| P577 | publication date | 2017-03-09 | |
| P1433 | published in | Targeted oncology | Q25378200 |
| P1476 | title | The Multifaceted Roles of B Cells in Solid Tumors: Emerging Treatment Opportunities | |
| P478 | volume | 12 |
| Q98177427 | Advances in Molecular Mechanisms for Traditional Chinese Medicine Actions in Regulating Tumor Immune Responses |
| Q90484027 | B Cells as Prognostic Biomarker After Surgery for Colorectal Liver Metastases |
| Q102152436 | Defining HPV-specific B cell responses in patients with head and neck cancer |
| Q89556686 | Immune crosstalk in cancer progression and metastatic spread: a complex conversation |
| Q64243266 | Obesity, Inflammation, and Prostate Cancer |
| Q55254953 | Pharmacological inactivation of the PI3K p110δ prevents breast tumour progression by targeting cancer cells and macrophages. |
| Q92288157 | The Prognostic Importance of CD20+ B lymphocytes in Colorectal Cancer and the Relation to Other Immune Cell subsets |
| Q49787788 | The influence of chemotherapy on adenosine-producing B cells in patients with head and neck squamous cell carcinoma |
| Q87944215 | [B cells in head and neck oncology] |
Search more.